{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05381909",
            "orgStudyIdInfo": {
                "id": "BGB-24714-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "CTR20232532",
                    "type": "OTHER",
                    "domain": "ChinaDrugTrials"
                }
            ],
            "organization": {
                "fullName": "BeiGene",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors",
            "officialTitle": "A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-bgb-as-monotherapy-and-with-combination-therapies-in-participants-with-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-16",
            "studyFirstSubmitQcDate": "2022-05-16",
            "studyFirstPostDateStruct": {
                "date": "2022-05-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BeiGene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult"
            ],
            "keywords": [
                "Solid tumors",
                "Advanced Solid Tumors",
                "Metastatic Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 210,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1a: Dose Escalation Part A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive escalating doses of BGB-24714 as monotherapy",
                    "interventionNames": [
                        "Drug: BGB-24714"
                    ]
                },
                {
                    "label": "Phase 1a: Dose Escalation Part B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive increasing dose levels of BGB-24714 in combination with paclitaxel",
                    "interventionNames": [
                        "Drug: BGB-24714",
                        "Drug: Paclitaxel"
                    ]
                },
                {
                    "label": "Phase 1a: Dose Escalation Part C",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation",
                    "interventionNames": [
                        "Drug: BGB-24714",
                        "Drug: Paclitaxel",
                        "Drug: Carboplatin"
                    ]
                },
                {
                    "label": "Phase 1a: Dose Escalation Part D",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation",
                    "interventionNames": [
                        "Drug: BGB-24714",
                        "Drug: Paclitaxel",
                        "Drug: Carboplatin"
                    ]
                },
                {
                    "label": "Phase 1a: Dose Escalation Part A-CN",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive escalating doses of BGB-24714 as monotherapy in Chinese participants",
                    "interventionNames": [
                        "Drug: BGB-24714"
                    ]
                },
                {
                    "label": "Phase 1a: Dose Escalation Part E",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation in Chinese participants",
                    "interventionNames": [
                        "Drug: BGB-24714",
                        "Drug: Paclitaxel",
                        "Drug: Carboplatin"
                    ]
                },
                {
                    "label": "Phase 1b: Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "BGB 24714 will be administered in combination with paclitaxel or docetaxel in participants with selected solid tumors.",
                    "interventionNames": [
                        "Drug: BGB-24714",
                        "Drug: Paclitaxel",
                        "Drug: Docetaxel"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BGB-24714",
                    "description": "administered orally",
                    "armGroupLabels": [
                        "Phase 1a: Dose Escalation Part A",
                        "Phase 1a: Dose Escalation Part A-CN",
                        "Phase 1a: Dose Escalation Part B",
                        "Phase 1a: Dose Escalation Part C",
                        "Phase 1a: Dose Escalation Part D",
                        "Phase 1a: Dose Escalation Part E",
                        "Phase 1b: Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Paclitaxel",
                    "description": "administered intravenously",
                    "armGroupLabels": [
                        "Phase 1a: Dose Escalation Part B",
                        "Phase 1a: Dose Escalation Part C",
                        "Phase 1a: Dose Escalation Part D",
                        "Phase 1a: Dose Escalation Part E",
                        "Phase 1b: Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "administered intravenously",
                    "armGroupLabels": [
                        "Phase 1a: Dose Escalation Part C",
                        "Phase 1a: Dose Escalation Part D",
                        "Phase 1a: Dose Escalation Part E"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Docetaxel",
                    "description": "administered intravenously",
                    "armGroupLabels": [
                        "Phase 1b: Dose Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose Escalation: Number of participants with adverse events (AEs)",
                    "description": "Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs ), and experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria.",
                    "timeFrame": "approximately 6 months"
                },
                {
                    "measure": "Dose Escalation: Maximum tolerated dose (MTD) of BGB-24714 as monotherapy, in combination with chemotherapy, and in combination with concurrent chemoradiotherapy (cCRT)",
                    "timeFrame": "approximately 6 months"
                },
                {
                    "measure": "Dose Escalation: Recommended Doses for Expansion (RDFE) of BGB-24714 as monotherapy, in combination with chemotherapy, and in combination with concurrent chemoradiotherapy (cCRT)",
                    "description": "Recommended dose based upon the MTD or MAD, as well as the long-term tolerability, pharmacokinetics, efficacy, and any other relevant data as available",
                    "timeFrame": "approximately 6 months"
                },
                {
                    "measure": "Dose Expansion: Objective response rate (ORR)",
                    "description": "ORR is defined as the percentage of participants with partial or complete response, as determined by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)",
                    "timeFrame": "approximately 2 Years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Dose Escalation: Objective response rate (ORR)",
                    "description": "ORR is defined as the percentage of participants with partial or complete response, as determined by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)",
                    "timeFrame": "approximately 2 Years"
                },
                {
                    "measure": "Dose Expansion: Progression-free Survival (PFS)",
                    "description": "PFS is defined as the time from the date of the first dose of study drug to the date of first documentation of disease progression as determined by the investigator using RECIST v1.1 or death, whichever occurs first",
                    "timeFrame": "approximately 2 Years"
                },
                {
                    "measure": "Dose Expansion: Number of participants with adverse events",
                    "description": "Number of participants with AEs and SAEs",
                    "timeFrame": "approximately 2 Years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first as determined by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)",
                    "timeFrame": "approximately 2 Years"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "DCR is defined as the percentage of participants whose best overall response is complete response, partial response, or stable disease, as determined by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)",
                    "timeFrame": "approximately 2 Years"
                },
                {
                    "measure": "Clinical Benefit Rate (CBR)",
                    "description": "CBR is defined as the percentage of participants who have complete response, partial response, and stable disease, as determined by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)",
                    "timeFrame": "approximately 2 Years"
                },
                {
                    "measure": "Plasma Concentrations of BGB-24714 and its metabolite",
                    "timeFrame": "approximately 2 Years"
                },
                {
                    "measure": "Maximum Observed Plasma Concentration (Cmax) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Time to Maximum Plasma Concentration (Tmax) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Terminal Half-life (t1/2) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Area Under the Plasma Concentration Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Area Under The Plasma Concentration Time Curve From Time 0 To Infinity (AUC0-inf) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Apparent Clearance (CL/F) of BGB-24714",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Apparent Volume Of Distribution (Vz/F) of BGB-24714",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Concentration at steady state (Cmax,ss) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Time to Maximum Plasma Concentration at steady state (Tmax,ss) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Area Under the Plasma Concentration Time Curve from Time 0 to the Last Quantifiable Concentration at Steady State (AUClast,ss) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                },
                {
                    "measure": "Rough Concentration At Steady State (Ctrough,ss) of BGB-24714 and its metabolite",
                    "timeFrame": "Up to 48 hours postdose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Eligibility Criteria :\n\n1. Participants must sign a written informed consent form (ICF); and agree to comply with study requirement\n2. Phase 1a (Dose Escalation):\n\n   Part A, A-CN, and B: Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumor previously treated with standard systemic therapy or for whom treatment is not available or not tolerated Note: Only Chinese participants will be eligible for Part A-CN.\n\n   Part C: Participant has histologically or cytologically confirmed, locally advanced, unresectable Stage III Non-small cell lung cancer (NSCLC) suitable for definitive chemoradiotherapy (CRT)\n\n   Part D: Participant with locally advanced, histologically confirmed inoperable esophageal squamous cell carcinoma (ESCC) suitable for definitive CRT\n\n   Phase 1b (Dose Expansion): Participants with histologically or cytologically confirmed solid tumors of selected types previously treated with standard therapy.\n3. Participants must be able to provide formalin-fixed paraffin embedded (FFPE) tumor tissue sample.\n4. Phase 1a Part A, A-CN, B and Phase 1b: \u2265 1 measurable lesion per Response evaluation criteria in solid tumors (RECIST) v1.1\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1\n\nKey Exclusion Criteria:\n\n1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.\n2. Any malignancy \u2264 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent\n3. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication \u2264 14 days before the first dose of study drug(s).\n4. Clinically significant infection requiring systemic therapy \u2264 14 days before the first dose of study drug(s).\n5. Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists.\n\nNOTE: Other protocol defined inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BeiGene",
                    "role": "CONTACT",
                    "phone": "1-877-828-5568",
                    "email": "ClinicalTrials@beigene.com"
                }
            ],
            "locations": [
                {
                    "facility": "Banner Md Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Gilbert",
                    "state": "Arizona",
                    "zip": "85234",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.35283,
                        "lon": -111.78903
                    }
                },
                {
                    "facility": "Florida Cancer Specialist (Scri) Sarasota",
                    "status": "RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Upmc Hillman Cancer Center(Univ of Pittsburgh)",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Tennessee Oncology, Pllc Nashville",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University of Texas Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "The University of Texas Md Anderson Cancer Center (Department Gi Medical Oncology)",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "University of Washington",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Princess Alexandra Hospital",
                    "status": "RECRUITING",
                    "city": "Brisbane",
                    "state": "Queensland",
                    "zip": "4102",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.46794,
                        "lon": 153.02809
                    }
                },
                {
                    "facility": "Icon Cancer Care South Brisbane",
                    "status": "RECRUITING",
                    "city": "South Brisbane",
                    "state": "Queensland",
                    "zip": "4101",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.48034,
                        "lon": 153.02049
                    }
                },
                {
                    "facility": "Austin Health",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "state": "Victoria",
                    "zip": "3084",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.75,
                        "lon": 145.06667
                    }
                },
                {
                    "facility": "Chongqing Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Chongqing",
                    "state": "Chongqing",
                    "zip": "400030",
                    "country": "China",
                    "geoPoint": {
                        "lat": 29.56278,
                        "lon": 106.55278
                    }
                },
                {
                    "facility": "Henan Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Zhengzhou",
                    "state": "Henan",
                    "zip": "450000",
                    "country": "China",
                    "geoPoint": {
                        "lat": 34.75778,
                        "lon": 113.64861
                    }
                },
                {
                    "facility": "Hunan Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Changsha",
                    "state": "Hunan",
                    "zip": "410013",
                    "country": "China",
                    "geoPoint": {
                        "lat": 28.19874,
                        "lon": 112.97087
                    }
                },
                {
                    "facility": "Shandong Provincial Hospital",
                    "status": "RECRUITING",
                    "city": "Jinan",
                    "state": "Shandong",
                    "zip": "250021",
                    "country": "China",
                    "geoPoint": {
                        "lat": 36.66833,
                        "lon": 116.99722
                    }
                },
                {
                    "facility": "Shandong Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Jinan",
                    "state": "Shandong",
                    "zip": "250117",
                    "country": "China",
                    "geoPoint": {
                        "lat": 36.66833,
                        "lon": 116.99722
                    }
                },
                {
                    "facility": "National Cancer Center",
                    "status": "RECRUITING",
                    "city": "Goyangsi",
                    "state": "Gyeonggido",
                    "zip": "10408",
                    "country": "Korea, Republic of"
                },
                {
                    "facility": "Seoul National University Bundang Hospital",
                    "status": "RECRUITING",
                    "city": "Seongnamsi",
                    "state": "Gyeonggido",
                    "zip": "13620",
                    "country": "Korea, Republic of"
                },
                {
                    "facility": "The Catholic University of Korea, St Vincents Hospital",
                    "status": "RECRUITING",
                    "city": "Suwonsi",
                    "state": "Gyeonggido",
                    "zip": "16247",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.29111,
                        "lon": 127.00889
                    }
                },
                {
                    "facility": "Gachon University Gil Medical Center",
                    "status": "RECRUITING",
                    "city": "Incheon",
                    "state": "Incheon Gwang'yeogsi",
                    "zip": "21565",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.45646,
                        "lon": 126.70515
                    }
                },
                {
                    "facility": "Severance Hospital Yonsei University Health System",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Auckland City Hospital",
                    "status": "RECRUITING",
                    "city": "Auckland",
                    "zip": "1023",
                    "country": "New Zealand",
                    "geoPoint": {
                        "lat": -36.84853,
                        "lon": 174.76349
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000077143",
                    "term": "Docetaxel"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1668",
                    "name": "Docetaxel",
                    "asFound": "Management",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}